Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Modulation of Inflammatory Arthritis in Mice by Gut Microbiota Through Mucosal Inflammation and Autoantibody Generation.

Jubair WK, Hendrickson JD, Severs EL, Schulz HM, Adhikari S, Ir D, Pagan JD, Anthony RM, Robertson CE, Frank DN, Banda NK, Kuhn KA.

Arthritis Rheumatol. 2018 Aug;70(8):1220-1233. doi: 10.1002/art.40490. Epub 2018 Jul 2.

PMID:
29534332
2.

'Happy the man, who, studying nature's laws, Thro' known effects can trace the secret cause.' Do we have enough pieces to solve the pyrazinamide puzzle?

Anthony RM, den Hertog AL, van Soolingen D.

J Antimicrob Chemother. 2018 Mar 8. doi: 10.1093/jac/dky060. [Epub ahead of print]

PMID:
29528413
3.

Correction: Variability and cost implications of three generations of the Roche LightCycler® 480.

Dullaert-de Boer M, Akkerman OW, Vermeer M, Hess DLJ, Kerstjens HAM, Anthony RM, van der Werf TS, van Soolingen D, van der Zanden AGM.

PLoS One. 2018 Feb 9;13(2):e0192946. doi: 10.1371/journal.pone.0192946. eCollection 2018.

4.

Pound foolish and penny wise-when will dosing of rifampicin be optimised?

Magis-Escurra C, Anthony RM, van der Zanden AGM, van Soolingen D, Alffenaar JC.

Lancet Respir Med. 2018 Apr;6(4):e11-e12. doi: 10.1016/S2213-2600(18)30044-4. Epub 2018 Jan 29. No abstract available.

PMID:
29396032
5.

Variability and cost implications of three generations of the Roche LightCycler® 480.

Dullaert-de Boer M, Akkerman OW, Vermeer M, Hess DLJ, Kerstjens HAM, Anthony RM, van der Werf TS, van Soolingen D, van der Zanden AGM.

PLoS One. 2018 Jan 12;13(1):e0190847. doi: 10.1371/journal.pone.0190847. eCollection 2018. Erratum in: PLoS One. 2018 Feb 9;13(2):e0192946.

6.

Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease.

Pagan JD, Kitaoka M, Anthony RM.

Cell. 2018 Jan 25;172(3):564-577.e13. doi: 10.1016/j.cell.2017.11.041. Epub 2017 Dec 21.

PMID:
29275858
7.

Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention.

Nguyen TVA, Anthony RM, Bañuls AL, Nguyen TVA, Vu DH, Alffenaar JC.

Clin Infect Dis. 2018 May 2;66(10):1625-1630. doi: 10.1093/cid/cix992.

PMID:
29126225
8.

Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140.

Mehta S, Cronkite DA, Basavappa M, Saunders TL, Adiliaghdam F, Amatullah H, Morrison SA, Pagan JD, Anthony RM, Tonnerre P, Lauer GM, Lee JC, Digumarthi S, Pantano L, Ho Sui SJ, Ji F, Sadreyev R, Zhou C, Mullen AC, Kumar V, Li Y, Wijmenga C, Xavier RJ, Means TK, Jeffrey KL.

Sci Immunol. 2017 Mar 3;2(9). pii: eaag3160. doi: 10.1126/sciimmunol.aag3160. Epub 2017 Mar 3.

9.

Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.

Sengstake S, Bergval IL, Schuitema AR, de Beer JL, Phelan J, de Zwaan R, Clark TG, van Soolingen D, Anthony RM.

BMC Infect Dis. 2017 Jul 12;17(1):491. doi: 10.1186/s12879-017-2594-3.

10.

Detection of tuberculosis drug resistance: a comparison by Mycobacterium tuberculosis MLPA assay versus Genotype®MTBDRplus.

Santos PFGD, Costa ERD, Ramalho DM, Rossetti ML, Barcellos RB, Nunes LS, Esteves LS, Rodenbusch R, Anthony RM, Bergval I, Sengstake S, Viveiros M, Kritski A, Oliveira MM.

Mem Inst Oswaldo Cruz. 2017 Jun;112(6):396-403. doi: 10.1590/0074-02760160376.

11.

Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.

Anthony RM, Cynamon M, Hoffner S, Werngren J, den Hertog AL, van Soolingen D.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00258-17. doi: 10.1128/AAC.00258-17. Print 2017 Jun. No abstract available.

12.

Sputum Microscopy and Mycobacterium tuberculosis Infectiousness.

Anthony RM.

J Infect Dis. 2017 Sep 1;216(5):507-508. doi: 10.1093/infdis/jix231. No abstract available.

PMID:
28510701
13.

In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.

Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ.

Sci Transl Med. 2017 May 10;9(389). pii: eaal3604. doi: 10.1126/scitranslmed.aal3604.

14.

New insights into the mechanism of action of pyrazinamide, implications for susceptibility testing, and future regimens.

Anthony RM, den Hertog A, Mansjö M, Werngren J.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S71-S72. doi: 10.1016/j.ijmyco.2016.08.009. Epub 2016 Sep 20.

15.

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.

Alffenaar JC, Akkerman OW, Anthony RM, Tiberi S, Heysell S, Grobusch MP, Cobelens FG, Van Soolingen D.

Expert Rev Anti Infect Ther. 2017 Jan;15(1):11-21. Epub 2016 Oct 24. Review.

PMID:
27762157
16.

Dual action of neurokinin-1 antagonists on Mas-related GPCRs.

Azimi E, Reddy VB, Shade KC, Anthony RM, Talbot S, Pereira PJ, Lerner EA.

JCI Insight. 2016 Oct 6;1(16):e89362.

17.

Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.

den Hertog AL, Menting S, Pfeltz R, Warns M, Siddiqi SH, Anthony RM.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4956-60. doi: 10.1128/AAC.00654-16. Print 2016 Aug.

18.

Recombination in pe/ppe genes contributes to genetic variation in Mycobacterium tuberculosis lineages.

Phelan JE, Coll F, Bergval I, Anthony RM, Warren R, Sampson SL, Gey van Pittius NC, Glynn JR, Crampin AC, Alves A, Bessa TB, Campino S, Dheda K, Grandjean L, Hasan R, Hasan Z, Miranda A, Moore D, Panaiotov S, Perdigao J, Portugal I, Sheen P, de Oliveira Sousa E, Streicher EM, van Helden PD, Viveiros M, Hibberd ML, Pain A, McNerney R, Clark TG.

BMC Genomics. 2016 Feb 29;17:151. doi: 10.1186/s12864-016-2467-y.

19.

The potential of a multiplex high-throughput molecular assay for early detection of first and second line tuberculosis drug resistance mutations to improve infection control and reduce costs: a decision analytical modeling study.

Van't Hoog AH, Bergval I, Tukvadze N, Sengstake S, Aspindzelashvili R, Anthony RM, Cobelens F.

BMC Infect Dis. 2015 Oct 26;15:473. doi: 10.1186/s12879-015-1205-4.

20.

Cytokine Kinetics in the First Week of Tuberculosis Therapy as a Tool to Confirm a Clinical Diagnosis and Guide Therapy.

den Hertog AL, Montero-Martín M, Saunders RL, Blakiston M, Menting S, Sherchand JB, Lawson L, Oladimeji O, Abdurrahman ST, Cuevas LE, Anthony RM.

PLoS One. 2015 Jun 26;10(6):e0129552. doi: 10.1371/journal.pone.0129552. eCollection 2015.

21.

Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite?

den Hertog AL, Sengstake S, Anthony RM.

Pathog Dis. 2015 Aug;73(6):ftv037. doi: 10.1093/femspd/ftv037. Epub 2015 May 19. Review.

PMID:
25994506
22.

A single glycan on IgE is indispensable for initiation of anaphylaxis.

Shade KT, Platzer B, Washburn N, Mani V, Bartsch YC, Conroy M, Pagan JD, Bosques C, Mempel TR, Fiebiger E, Anthony RM.

J Exp Med. 2015 Apr 6;212(4):457-67. doi: 10.1084/jem.20142182. Epub 2015 Mar 30.

23.

IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses.

Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, Dehlink E, Shade KT, Anthony RM, Blumberg RS, Turley SJ, Fiebiger E.

Cell Rep. 2015 Mar 3. pii: S2211-1247(15)00143-6. doi: 10.1016/j.celrep.2015.02.015. [Epub ahead of print]

24.

A proportion of mutations fixed in the genomes of in vitro selected isogenic drug-resistant Mycobacterium tuberculosis mutants can be detected as minority variants in the parent culture.

Bergval I, Coll F, Schuitema A, de Ronde H, Mallard K, Pain A, McNerney R, Clark TG, Anthony RM.

FEMS Microbiol Lett. 2015 Jan;362(2):1-7. doi: 10.1093/femsle/fnu037. Epub 2014 Dec 4.

25.

Mycobacterium tuberculosis Beijing genotype resistance to transient rifampin exposure.

den Hertog AL, Menting S, van Soolingen D, Anthony RM.

Emerg Infect Dis. 2014 Nov;20(11):1932-3. doi: 10.3201/eid2011.130560. No abstract available.

26.

Evaluation of a microcolony growth monitoring method for the rapid determination of ethambutol resistance in Mycobacterium tuberculosis.

den Hertog AL, Menting S, Smienk ET, Werngren J, Hoffner S, Anthony RM.

BMC Infect Dis. 2014 Jul 10;14:380. doi: 10.1186/1471-2334-14-380.

27.

Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling.

Wermeling F, Anthony RM, Brombacher F, Ravetch JV.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13487-91. doi: 10.1073/pnas.1312525110. Epub 2013 Jul 29.

28.

No added value of performing Ziehl-Neelsen on auramine-positive samples for tuberculosis diagnostics.

den Hertog AL, Daher S, Straetemans M, Scholing M, Anthony RM.

Int J Tuberc Lung Dis. 2013 Aug;17(8):1094-9. doi: 10.5588/ijtld.12.0773.

PMID:
23827035
29.

Early specific host response associated with starting effective tuberculosis treatment in an infection controlled placebo controlled mouse study.

den Hertog AL, de Vos AF, Klatser PR, Anthony RM.

PLoS One. 2013;8(2):e57997. doi: 10.1371/journal.pone.0057997. Epub 2013 Feb 28.

30.

Re-think first-line tuberculosis treatment.

van Ingen J, Anthony RM.

Eur Respir J. 2013 Feb;41(2):488-9. doi: 10.1183/09031936.00112612. No abstract available.

31.

Bead array direct rRNA capture assay (rCapA) for amplification free speciation of Mycobacterium cultures.

de Ronde H, González Alonso P, van Soolingen D, Klatser PR, Anthony RM.

PLoS One. 2012;7(3):e32575. doi: 10.1371/journal.pone.0032575. Epub 2012 Mar 2.

32.

Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing.

Streicher EM, Bergval I, Dheda K, Böttger EC, Gey van Pittius NC, Bosman M, Coetzee G, Anthony RM, van Helden PD, Victor TC, Warren RM.

Antimicrob Agents Chemother. 2012 May;56(5):2420-7. doi: 10.1128/AAC.05905-11. Epub 2012 Feb 13.

33.

Potential biomarkers for identification of mycobacterial cultures by proton transfer reaction mass spectrometry analysis.

Crespo E, de Ronde H, Kuijper S, Pol A, Kolk AH, Cristescu SM, Anthony RM, Harren FJ.

Rapid Commun Mass Spectrom. 2012 Mar 30;26(6):679-85. doi: 10.1002/rcm.6139.

PMID:
22328222
34.

Novel roles for the IgG Fc glycan.

Anthony RM, Wermeling F, Ravetch JV.

Ann N Y Acad Sci. 2012 Apr;1253:170-80. doi: 10.1111/j.1749-6632.2011.06305.x. Epub 2012 Jan 30. Review.

PMID:
22288459
35.

Simple rapid near-patient diagnostics for tuberculosis remain elusive--is a "treat-to-test" strategy more realistic?

den Hertog AL, Mayboroda OA, Klatser PR, Anthony RM.

PLoS Pathog. 2011 Nov;7(11):e1002207. doi: 10.1371/journal.ppat.1002207. Epub 2011 Nov 3. No abstract available.

36.

Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.

Anthony RM, Kobayashi T, Wermeling F, Ravetch JV.

Nature. 2011 Jun 19;475(7354):110-3. doi: 10.1038/nature10134.

37.

Genetic therapies for cystic fibrosis lung disease.

Sinn PL, Anthony RM, McCray PB Jr.

Hum Mol Genet. 2011 Apr 15;20(R1):R79-86. doi: 10.1093/hmg/ddr104. Epub 2011 Mar 21. Review.

38.

Proton Transfer Reaction Mass Spectrometry detects rapid changes in volatile metabolite emission by Mycobacterium smegmatis after the addition of specific antimicrobial agents.

Crespo E, Cristescu SM, de Ronde H, Kuijper S, Kolk AH, Anthony RM, Harren FJ.

J Microbiol Methods. 2011 Jul;86(1):8-15. doi: 10.1016/j.mimet.2011.01.025. Epub 2011 Jan 28.

PMID:
21277343
39.

The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo.

Anthony RM, Nimmerjahn F.

Curr Opin Organ Transplant. 2011 Feb;16(1):7-14. doi: 10.1097/MOT.0b013e328342538f. Review.

PMID:
21150612
40.

Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas.

Cheong C, Matos I, Choi JH, Dandamudi DB, Shrestha E, Longhi MP, Jeffrey KL, Anthony RM, Kluger C, Nchinda G, Koh H, Rodriguez A, Idoyaga J, Pack M, Velinzon K, Park CG, Steinman RM.

Cell. 2010 Oct 29;143(3):416-29. doi: 10.1016/j.cell.2010.09.039.

41.

Retooling national TB control programmes (NTPs) with new diagnostics: the NTP perspective.

van Kampen SC, Ramsay AR, Anthony RM, Klatser PR.

PLoS One. 2010 Jul 19;5(7):e11649. doi: 10.1371/journal.pone.0011649.

42.

A simple and rapid molecular method for Leptospira species identification.

Ahmed A, Anthony RM, Hartskeerl RA.

Infect Genet Evol. 2010 Oct;10(7):955-62. doi: 10.1016/j.meegid.2010.06.002. Epub 2010 Jun 12.

PMID:
20547247
43.

Simplified automated image analysis for detection and phenotyping of Mycobacterium tuberculosis on porous supports by monitoring growing microcolonies.

den Hertog AL, Visser DW, Ingham CJ, Fey FH, Klatser PR, Anthony RM.

PLoS One. 2010 Jun 8;5(6):e11008. doi: 10.1371/journal.pone.0011008.

44.

A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.

Anthony RM, Ravetch JV.

J Clin Immunol. 2010 May;30 Suppl 1:S9-14. doi: 10.1007/s10875-010-9405-6. Review.

PMID:
20480216
45.

The realistic performance achievable with mycobacterial automated culture systems in high and low prevalence settings.

van Kampen SC, Anthony RM, Klatser PR.

BMC Infect Dis. 2010 Apr 12;10:93. doi: 10.1186/1471-2334-10-93.

46.

Liquid culture for Mycobacterium tuberculosis: proceed, but with caution.

Anthony RM, Cobelens FG, Gebhard A, Klatser PR, Lumb R, Rüsch-Gerdes S, van Soolingen D.

Int J Tuberc Lung Dis. 2009 Sep;13(9):1051-3.

PMID:
19723391
47.

Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance.

Bergval IL, Schuitema AR, Klatser PR, Anthony RM.

J Antimicrob Chemother. 2009 Sep;64(3):515-23. doi: 10.1093/jac/dkp237. Epub 2009 Jul 4.

48.

Role of teichoic acid choline moieties in the virulence of Streptococcus pneumoniae.

Gehre F, Spisek R, Kharat AS, Matthews P, Kukreja A, Anthony RM, Dhodapkar MV, Vollmer W, Tomasz A.

Infect Immun. 2009 Jul;77(7):2824-31. doi: 10.1128/IAI.00986-08. Epub 2009 May 11.

49.

Buoyant density of Mycobacterium tuberculosis: implications for sputum processing.

den Hertog AL, Klatser PR, Anthony RM.

Int J Tuberc Lung Dis. 2009 Apr;13(4):466-71.

PMID:
19335952
50.

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC.

Nature. 2009 Apr 2;458(7238):636-40. doi: 10.1038/nature07930. Epub 2009 Mar 15.

PMID:
19287373

Supplemental Content

Loading ...
Support Center